Single Ascending Dose Study of PRX003 in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Psoriasis

In brief

This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 40 healthy subjects.

Key facts

Study ID

NCT02458677

Run by

Prothena Biosciences Limited

People needed

40

Starts

2015-05-01

Expected to finish

2016-02-01

Last updated by the study team

2016-03-16

Who can join

Age: 21 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects
• Body mass index (BMI) between 18-32 kg/m2 with a minimum weight of 45 kg
• Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception
• Male subjects and their partners of childbearing potential must use contraception

You may not qualify if…

• Positive test for drug of abuse
• Past or current history of alcohol abuse
• Positive for TB, hepatitis B, hepatitis C or HIV infection

Where it is running

• Worldwide Clinical Trials Early Phase Services — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.